Last week the Committee for Medicinal Products for Human Use (“CHMP”) of the European Medicines Agency (“EMA”) recommended two biosimilar medicines for approval.
First, the CHMP adopted a positive opinion for the marketing authorization of Kanjinti® (ABP 980), Amgen and Allergan’s proposed biosimilar to Herceptin® (trastuzumab). The CHMP opinion recommends Kanjinti® for approval for the treatment of the same three types of cancer as Herceptin® is approved for in the EU, including HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive metastatic adenocarcinoma of the stomach or gastroesophageal junction. In its press release, Amgen stated that the Marketing Authorization Application for Kanjinti® was supported by “analytical, pharmacokinetic and clinical data, as well as pharmacology and toxicology data,” and that its “Phase 3 comparative efficacy, safety and immunogenicity study was conducted in adult female patients with HER2-positive early breast cancer.”
Second, the CHMP adopted a positive opinion for marketing authorization of Zessly®, Sandoz’s proposed biosimilar to Remicade® (infliximab). The CHMP opinion recommends Zessly® for the treatment of all indications of Remicade®, including rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. In its press release, Sandoz stated that the CHMP’s opinion was based on a “comprehensive data package that is expected to confirm the biosimilarity of [Zessly®] to the reference medicine with analytical, preclinical and clinical data matching across quality, efficacy and safety,” and that its “clinical Phase III confirmatory study in rheumatoid arthritis (REFLECTIONS B537-02) met its primary endpoint, demonstrating equivalent efficacy of [Zessly®] to the reference medicine as measured by the American College of Rheumatology 20 (ACR20) response at Week 14.”
The post Amgen/Allergan & Sandoz Receive Positive CHMP Opinions appeared first on Big Molecule Watch.